Wed Dec 19, 2012 7:09am EST
(Reuters) – Biopharmaceutical association Oncothyreon Inc pronounced a late-stage hearing of a initial lung cancer drug did not accommodate a categorical investigate idea of improving altogether survival.
The drug, codenamed L-BLP25, is being tested in patients with unresectable, locally modernized theatre IIIA or theatre IIIB, non-small dungeon lung cancer (NSCLC).
The hearing was conducted by Merck Serono, a multiplication of Germany’s Merck KGaA, underneath a permit agreement with Oncothyreon.
(Reporting by Esha Dey in Bangalore; Editing by Roshni Menon)
More on: Health Medicine Network